COVID-19 Ibuprofen Fears Hit Advil Sales In GSK’s Q2
Reports that ibuprofen could worsen COVID-19 in the early months of the pandemic hit sales of GSK's leading Advil brand, contributing to a drop in pro-forma Consumer Healthcare turnover in the second quarter of 2020.
You may also be interested in...
Deal with Foundation Consumer Brands marks GSK’s latest sale of OTC and nutritional brands that aren’t strong enough revenue drivers to remain part of its consumer health JV with Pfizer. GSK has controlled the brands it’s divesting for less than a year.
Review by MHRA advisory body finds no issue with ibuprofen use in COVID-19 patients and updates advice to recommend either paracetamol or ibuprofen to treat symptoms.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.